XML 51 R37.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUES - Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Total revenues $ 6,423 $ 5,548
U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,260 4,006
Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,336 975
Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 827 567
Total product sales    
Disaggregation of Revenue [Line Items]    
Total revenues 6,340 5,467
Total product sales | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,240 3,989
Total product sales | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,275 927
Total product sales | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 825 551
Total HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 3,650 4,134
Total HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 2,786 3,253
Total HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 578 639
Total HIV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 286 242
Atripla    
Disaggregation of Revenue [Line Items]    
Total revenues 31 95
Atripla | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 23 81
Atripla | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 4 7
Atripla | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 4 7
Biktarvy    
Disaggregation of Revenue [Line Items]    
Total revenues 1,824 1,693
Biktarvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 1,465 1,412
Biktarvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 216 181
Biktarvy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 143 100
Complera/Eviplera    
Disaggregation of Revenue [Line Items]    
Total revenues 63 76
Complera/Eviplera | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 25 24
Complera/Eviplera | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 34 47
Complera/Eviplera | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 4 5
Descovy    
Disaggregation of Revenue [Line Items]    
Total revenues 359 458
Descovy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 282 363
Descovy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 42 61
Descovy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 35 34
Genvoya    
Disaggregation of Revenue [Line Items]    
Total revenues 673 824
Genvoya | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 506 612
Genvoya | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 106 151
Genvoya | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 61 61
Odefsey    
Disaggregation of Revenue [Line Items]    
Total revenues 367 409
Odefsey | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 240 269
Odefsey | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 113 127
Odefsey | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 14 13
Stribild    
Disaggregation of Revenue [Line Items]    
Total revenues 46 53
Stribild | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 31 34
Stribild | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 11 17
Stribild | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 4 2
Truvada    
Disaggregation of Revenue [Line Items]    
Total revenues 135 406
Truvada | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 119 383
Truvada | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 7 8
Truvada | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 9 15
Other HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 17 8
Other HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 6 3
Other HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1 2
Other HIV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 10 3
Revenue share - Symtuza    
Disaggregation of Revenue [Line Items]    
Total revenues 135 112
Revenue share - Symtuza | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 89 72
Revenue share - Symtuza | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 44 38
Revenue share - Symtuza | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 2 2
Total HCV    
Disaggregation of Revenue [Line Items]    
Total revenues 510 729
Total HCV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 258 398
Total HCV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 135 148
Total HCV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 117 183
Ledipasvir/Sofosbuvir    
Disaggregation of Revenue [Line Items]    
Total revenues 56 112
Ledipasvir/Sofosbuvir | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 19 53
Ledipasvir/Sofosbuvir | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 16 11
Ledipasvir/Sofosbuvir | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 21 48
Sofosbuvir/Velpatasvir    
Disaggregation of Revenue [Line Items]    
Total revenues 381 564
Sofosbuvir/Velpatasvir | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 214 311
Sofosbuvir/Velpatasvir | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 75 122
Sofosbuvir/Velpatasvir | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 92 131
Other HCV    
Disaggregation of Revenue [Line Items]    
Total revenues 73 53
Other HCV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 25 34
Other HCV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 44 15
Other HCV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 4 4
Total HBV/HDV    
Disaggregation of Revenue [Line Items]    
Total revenues 220 186
Total HBV/HDV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 81 85
Total HBV/HDV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 23 20
Total HBV/HDV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 116 81
Vemlidy    
Disaggregation of Revenue [Line Items]    
Total revenues 181 136
Vemlidy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 77 73
Vemlidy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 8 7
Vemlidy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 96 56
Viread    
Disaggregation of Revenue [Line Items]    
Total revenues 31 40
Viread | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4 4
Viread | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 7 11
Viread | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 20 25
Other HBV/HBD    
Disaggregation of Revenue [Line Items]    
Total revenues 8 10
Other HBV/HBD | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 0 8
Other HBV/HBD | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 8 2
Other HBV/HBD | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Veklury    
Disaggregation of Revenue [Line Items]    
Total revenues 1,456 0
Veklury | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 820 0
Veklury | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 388 0
Veklury | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 248 0
Total Cell Therapy    
Disaggregation of Revenue [Line Items]    
Total revenues 191 140
Total Cell Therapy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 119 103
Total Cell Therapy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 65 37
Total Cell Therapy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 7 0
Tecartus    
Disaggregation of Revenue [Line Items]    
Total revenues 31 0
Tecartus | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 27 0
Tecartus | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 4 0
Tecartus | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Yescarta    
Disaggregation of Revenue [Line Items]    
Total revenues 160 140
Yescarta | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 92 103
Yescarta | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 61 37
Yescarta | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 7 0
Trodelvy    
Disaggregation of Revenue [Line Items]    
Total revenues 72 0
Trodelvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 72 0
Trodelvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Trodelvy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Total Other    
Disaggregation of Revenue [Line Items]    
Total revenues 241 278
Total Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 104 150
Total Other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 86 83
Total Other | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 51 45
AmBisome    
Disaggregation of Revenue [Line Items]    
Total revenues 121 119
AmBisome | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 12 18
AmBisome | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 66 59
AmBisome | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 43 42
Letairis    
Disaggregation of Revenue [Line Items]    
Total revenues 54 83
Letairis | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 54 83
Letairis | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Letairis | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Ranexa    
Disaggregation of Revenue [Line Items]    
Total revenues 3 8
Ranexa | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 3 8
Ranexa | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Ranexa | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Zydelig    
Disaggregation of Revenue [Line Items]    
Total revenues 15 20
Zydelig | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 8 8
Zydelig | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 7 12
Zydelig | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Other    
Disaggregation of Revenue [Line Items]    
Total revenues 48 48
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 27 33
Other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 13 12
Other | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 8 3
Royalty, contract and other revenues    
Disaggregation of Revenue [Line Items]    
Total revenues 83 81
Royalty, contract and other revenues | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 20 17
Royalty, contract and other revenues | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 61 48
Royalty, contract and other revenues | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues $ 2 $ 16